Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

Similar documents
Deutsches Aortenklappenregister German Aortic Valve RegistrY

German Aortic Valve RegistrY

Aortic valve implantation using the femoral and apical access: a single center experience.

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

TAVI in Korea, How to Avoid Conduction

Maurizio D Amico M.D.

TAVI: Transapical Procedures

Results of Transfemoral Transcatheter Aortic Valve Implantation

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

1-YEAR OUTCOMES FROM JOHN WEBB, MD

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

The learning curve associated with transapical aortic valve implantation

Transcatheter aortic valve implantation and pre-procedural risk assesment

TAVR SPRING 2017 The evolution of TAVR

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong

SOLVE-TAV. Holger Thiele, MD on behalf of the SOLVE-TAVI Investigators

Early Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study

Aortic Stenosis: Background

Case Presentations TAVR: The Good Bad and The Ugly

LOW RISK TAVR. WHAT THE FUTURE HOLDS

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

In Process, Unpublished STS/ACC TVT Registry Manuscripts

Le TAVI pour tout le monde?

In Process, Unpublished STS/ACC TVT Registry Manuscripts

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

TAVR IN INTERMEDIATE-RISK PATIENTS

Emergency TAVI: Does It Exist? Is the Risk Higher?

Euro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI

Transcatheter Aortic Valve Replacement

Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI

TAVR for low-risk patients in 2017: not so fast.

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

A review of the complications associated with Transcatheter Aortic Valve Implantation.

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

TAVI: Nouveaux Horizons

TAVR: Echo Measurements Pre, Post And Intra Procedure

VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

The Role of TAVI in high-risk and normal-risk Patients

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Peter F Ludman BCIS National Audit Lead

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

How to manage TAVI related vascular complications. Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI

TAVI After PARTNER-2 : The Hamilton Approach

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Magdalena Erlebach 1, Michael Wottke 1, Marcus-André Deutsch 1, Markus Krane 1, Nicolo Piazza 2, Ruediger Lange 1, Sabine Bleiziffer 1

Effect of Concomitant Coronary Artery Disease on Procedural and Late Outcomes of Transcatheter Aortic Valve Implantation

Vinod H. Thourani, MD, FACC, FACS

Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Nouvelles indications/ Nouvelles valves

TAVR: Review of the Robust Data from Randomized Trials

ADVANCED TAVI IMAGING

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

How to Prevent Thromboembolic Complications in TAVI

Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis

History. 2D echo before TAVI. 88 female Hypertensive - hyperlipidemic History of LOC syncope Echo: severe AS AV gradient 90 mmhg Good LV LVH

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Results of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery

Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

TAVI Implantation: Rapid Pacing, Pre and Post Dilatation

For the SURTAVI Investigators

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

Outcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

Supplementary Online Content

Alex versus Xience Registry Preliminary report

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center

Left ventricular function determines the survival benefit for women over men after transcatheter aortic valve implantation (TAVI)

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

Minimally invasive aortic valve surgery: new solutions to old problems.

Management of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Transcription:

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch, Joachim Kötting, Norman Mangner, Harald Mudra, Andreas Beckmann, Jochen Cremer, Armin Welz, Rüdiger Lange, Karl-Heinz Kuck, Friedrich W. Mohr, and Helge Möllmann on behalf of the GARY executive board Hotline session ACC March 15, 2015 online publication JACC

Procedures German AV registry nationwide registry on AVR + T-AVI 93 active hospitals; 82,577 consented pat. 12/14 Documented Procedures since 2010 25,710 consented patients in 2014 25.000 20.000 Total AVR V-TAVI A-TAVI 17.229 20.122 Total: 53.649 15.000 10.000 14.370 10.001 11.203 12.951 AVR: 35.393 Documentation in Progress 5.000 0 4.677 3.906 2.727 1.928 1.238 440 173 1.186 1.501 1.619 2010 2011 2012 2013 2014 Year V-TAVI: 11.750 A-TAVI: 4.479

T-AVI patients 2011-13 n = 15,964 retrograde transfemoral: n = 11,292 70.7% antegrade transapical: n = 4,304 27% alternative access: n = 368 2.3% In-hospital outcome data were analyzed.

Valves implanted T-AVI 2011-2013 n = 15,964 Balloon expandable (SAPIEN XT, SAPIEN 3 ) 52.6% n = 8,390 Self expandable (Corevalve ) 37.7% n = 6,026 Self expandable and Other 9.7% n = 1,548

Definitions Severe vital complications (SVC): death on day of intervention, conversion to sternotomy, acute PCI, low cardiac output requiring mechanical circulatory support, cardiac tamponade requiring treatment, aortic dissection, annular rupture Technical complications of the procedures (TCO): repositioning or retrieval of valve prosthesis, valve-in-valve procedure, valve embolization, closure of a paravalvular leak Other complications: aortic regurgitation, new-onset pacemaker implantation, stroke, major vascular complications, major bleeding Conversion to sternotomy In-hospital death

Baseline data Total Patients 100 % Female 54 % Age [years] 81 ±6 Euroscore [Median] 18.3 GER AV Sc. [Median] STS Score [Median] 5.6 5.0 NYHA III IV 86 % * indicates p<0.01 versus all other patients

Baseline data Total SVC TCO Sternotomy Death Patients 100 % 5.0% 4.7% 1.3% 5.2% Female 54 % Age [years] 81 ±6 Euroscore [Median] 18.3 GER AV Sc. [Median] STS Score [Median] 5.6 5.0 NYHA III IV 86 % * indicates p<0.01 versus all other patients

Baseline data Total SVC TCO Sternotomy Death Patients 100 % 5.0% 4.7% 1.3% 5.2% Female 54 % 59.5% * 47.6% * 59.2% 53.4% * Age [years] 81 ±6 81.0 ±6.2 81.0 ±6.0 80.5 ±5.6 81.6 ±6.3 Euroscore [Median] 18.3 21.0 * 21.5 * 20.6 24.7 * GER AV Sc. [Median] STS Score [Median] 5.6 6.1 * 6.1 * 5.8 * 8.1 * 5.0 5.7 * 5.5 * 5.5 * 6.9 * NYHA III IV 86 % 88.0% 86.1% 88.6% 90.2% * * indicates p<0.01 versus all other patients

Baseline data (b) Total SVC TCO Sternotomy Death Patients 100% 5.0% 4.7% 1.3% 5.2% CAD 55.1% 58.0% 58.2% 50.2% 61.8% * Previous card. Surgery 21.0% 23.0% 25.1% * 19.4% 23.3% Pulmonary hypertension 35.7% 35.6% 35.9% 34.2% 45.4% * COPD requ.med. 14.2% 12.8% 13.8% 11.9% 16.2% EF < 30% 9.5% 12.8% * 13.6% * 8.5% 16.3% * Renal repl. tx. 5.0% 4.8% 5.2% 5.5% 8.2% * Peripheral vasc. disease 19.5% 22.3% * 19.7% 22.4% 30.1% * * indicates p<0.01 versus all other patients

Procedural data Total SVC TCO Sternotomy Death Patients 15,964 792 748 201 828 In-hospital mortality 5.2% 40.8% * 17.1% * 42.3% * 100% * indicates p<0.01 versus all other patients

Total SVC TCO Sternotomy Death Patients 15,964 792 748 201 828 In-hospital 5.2% 40.8% * 17.1% * 42.3% * 100% mortality CPB used 2.4% 28.7% * 13.9% * 56.7% * 13.6% * Conversion open heart surgery Cardiac tamponade Transfemoral approach Transapical approach * indicates p<0.01 versus all other patients Procedural data 1.3% 25.4% * 12.0% * 100.0% * 10.3% * 1.0% 20.7% * 3.9% * 31.5% * 8.0% * 70.7% 66.3% * 79.0% * 67.7% 58.6% * 27.0% 31.3% * 20.2% * 30.3% 37.6% *

Other complications Total SVC TCO Sternotomy Death Patients 15,964 792 748 201 828 Residual AR 2 New-onset pacer implant 5.8% 10.7% * 12.8% * 16.7% * 12.0% * 17.5% 13.3% * 25.2% * 12.8% 13.9% * Stroke 1.5% 4.2% * 4.1% * 3.5% * 6.3% * Major vasc. complication 4.1% 8.0% * 10.3% * 7.0% * 8.0% * Major bleeding # 26.3% 54.7% * 40.3% * 70.1% * 59.8% * * indicates p<0.01 versus all other patients # VARC II definition, 2 RBC units

Predictors for death OR 95% conf. interval p Residual aortic regurgitation 2 1.885 1.372 2.588 0.000 Peripheral vascular disease 1.443 1.156 1.800 0.001 Mitral regurgitation > 2 1.324 1.079 1.624 0.007 Ejection fraction < 30% 1.573 1.184 2.092 0.002 Pulmonary hypertension 1.353 1.106 1.655 0.003 NYHA class IV 1.288 0.999 1.661 0.051 Body mass index < 22 1.586 1.227 2.049 0.000 Sternotomy 2.078 1.208 3.573 0.008 Low cardiac output 8.850 6.039 12.971 0.000 Cardiogenic shock 1.952 1.296 2.941 0.001 Tamponade 3.743 2.121 6.606 0.000 Aortic dissection 5.594 2.023 15.470 0.001 Annular rupture 7.058 3.202 15.559 0.000 PCI due to complications 2.841 1.253 6.439 0.012 Technical complications 1.638 1.155 2.323 0.006 Post-operative stroke 3.574 2.301 5.550 0.000 Post-operative new-onset dialysis 10.519 8.137 13.599 0.000 Post-operative myocardial infarction 23.146 10.877 49.251 0.000 Post-operative ischemia 2.101 1.085 4.068 0.028 Bleeding 5.005 3.961 6.325 0.000 Severe vital complications (SVC) multivariate analysis

multivariate analysis Predictors for SVC OR 95% conf. interval p Female gender 1.37 1.16 1.62 0.0002 NYHA class IV 1.46 1.19 1.79 0.0003 LVEF 30 % 1.33 1.05 1.70 0.0183 i.v. Inotropes 3.88 2.92 5.16 0.0000 Arterial vascular disease 1.23 1.04 1.45 0.0159 Higher degree of calcification 1.28 1.07 1.52 0.0059 Higher degree of aortic stenosis 1.36 1.14 1.62 0.0007

multivariate analysis Predictors for TCO OR 95% conf. interval p Year of.882.803.969 0.009 procedure Male gender 1.287 1.106 1.499 0.001 LVEF 30 % 1.39 1.11 1.74 0.005 Neurological 0.000 dysfunction 1.43 1.17 1.74 Cardiac 0.015 decompensation 1.21 1.04 1.41 i.v. Inotropes 2.22 1.59 3.11 0.000

multivariate analysis Predictors for Sternotomy OR 95% conf. interval p none

Regression in risk profiles Total 2011 2012 2013 p 100% 24.7% 34.6% 40.6% Log ES [mean / median] 23.3 18.3 25.4 20.2 23.5 18.6 21.9 16.9 < 0.001 German AV Score [mean / median] 7.7 5.6 8.4 5.8 7.7 5.6 7.2 5.2 < 0.001 STS Score [mean / median] 6.4 5.0 6.7 5.2 6.3 5.0 6.4 4.9 < 0.001

Overall incidence of complications in % Total SVC TCO Sternotomy Death Patients 100 5.0 4.7 1.3 5.2 2011 100 6.8 5.3 1.6 5.9 2012 100 4.9 5.0 1.2 5.0 2013 100 3.9 4.0 1.1 4.9 p - < 0.001 0.003 0.133 0.078 SVC = severe vital complication TCO = technical complication

Conclusions: T-AVI T-AVI is safe with acceptable complication rates, all-comers and high-risk population (n= 15,964) Decrease in complications over years: (learnings, screening+selection, technical progress) Severe vital complications + TCO remain ~ 4 %. Independent predictors for complications (p<0.01): (gender, reduced ejection fraction, arterial vascular disease) Sternotomy stable at ~ 1.2 %, no predictors In-hospital death rate ~ 5 %, no change

Thank you!